A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Poland
Department of Dermatology, Venereology and Allergology, University Clinical Centre, Gdansk, Poland
Adv
Dermatol Allergol
-
Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci 2021; 22: 4130.
Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol 2022; 36: 1409-31.
Nowicki R, Trzeciak M, Rudnicka L, et al. Biological drugs in the treatment of atopic dermatitis – recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine. Pol J Allergol 2020; 7: 171-9.
Nowicki R, Trzeciak M, Kaczmarski M, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part II. Systemic treatment and new therapeutic methods. Dermatol Rev 2019; 106: 475-85.
U.S. Food and Drug Administration. Label information for drug Dupixent. Updated 2025. Accessed June 1, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761055s051lbl.pdf
Sroka-Tomaszewska J, Buliñska B, Wilkowska A, et al. Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience. Adv Dermatol Allergol 2023; 40: 747-52.
Strong A, Lin T, Sverrild A, et al. Dupilumab-associated hypereosinophilia in severe asthma. ERJ Open Res 2024; 10: 00048-02024.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-303.
Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2020; 21: 567-77.
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis. JAMA Dermatol 2020; 156: 44-56.
Siegfried EC, Cork MJ, Katoh N, et al. Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: post hoc analysis results from a phase III trial. Am J Clin Dermatol 2023; 24: 787-98.
Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 2022; 23: 365-83.
Napolitano M, Fabbrocini G, Potestio L, et al. A 24‐weeks real‐world experience of dupilumab in adolescents with moderate‐to‐severe atopic dermatitis. Dermatol Ther 2022; 35: e15588.
Stingeni L, Hansel K, Antonelli E, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther 2021; 34: e15035.
Stingeni L, Bianchi L, Antonelli E, et al. Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real‐world experience. J Eur Acad Dermatol Venereol 2022; 36: 1292-9.
Napolitano M, Fabbrocini G, Neri I, et al. Dupilumab treatment in children aged 6–11 years with atopic dermatitis: a multicentre, real-life study. Pediatric Drugs 2022; 24: 671-8.
Kiefer S, König A, Gerger V, et al. Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study. J Clin Med 2023; 12: 1175.
Martinez‐Cabriales S, Marcoux D, Liy‐Wong C, et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab. Pediatr Dermatol 2024; 41: 5-11.
Zhou B, Peng C, Cao Q, et al. Dupilumab therapy in children aged 2–12 years with uncontrolled moderate‐to‐severe atopic dermatitis: a Chinese real‐world study. J Eur Acad Dermatol Venereol 2024; 38: e35-8.
Wang Y, Shen C, Liu D, et al. Dupilumab improves clinical scores in pediatric patients aged 2 to <18 years with uncontrolled atopic dermatitis: a single‐center, real‐world study. Dermatol Ther 2023; 2023; 5626410.
Patruno C, Fabbrocini G, Lauletta G, et al. A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years. J Dermatol Treat 2023; 34: 2246602.
Pagan AD, David E, Ungar B, et al. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study. J Allergy Clin Immunol Pract 2022; 10: 2378-85.
Hosseini-Ashrafi M, Clayton TH, Herring M, et al. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Clin Exp Dermatol 2024; 49: 578-83.
Jang DH, Heo SJ, Kook HD, et al. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Sci Rep 2021; 11: 23539.
Metko D, Alkofide M, Abu-Hilal M. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int 2024; 15: 5-11.
Ariëns LFM, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-9.
Nettis E, Fabbrocini G, Ortoncelli M, et al. Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br J Dermatol 2021; 184: 561-3.
Nakajima H, Kamata M, Okada Y, et al. Real‐world experience of 3‐year treatment with dupilumab: significant decrease in circulating neutrophils and eosinophils in Japanese patients with atopic dermatitis. Exp Dermatol 2024; 33: e70010.
Torres T, Cruz MJ, Gonçalo M, et al. Dupilumab in patients with atopic dermatitis: a multicentric, long-term, real-world Portuguese study. Dermatol Ther 2024; 14: 2209-21.
Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis. J Eur Acad Dermatol Venereol 2023; 37: 1046-55.
Kojanova M, Tanczosova M, Strosova D, et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatol Treat 2022; 33: 2578-86.
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282-93.
Akinlade B, Guttman‐Yassky E, Bruin‐Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459-73.
Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-51.
Ferreira S, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs Context 2020; 9: 1-8.
Paller AS, Wollenberg A, Siegfried E, et al. Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis: results from a phase III clinical trial. Pediatr Drugs 2021; 23: 515-27.
Siegfried EC, Bieber T, Simpson EL, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo-controlled, phase 3 clinical trial. Am J Clin Dermatol 2021; 22: 243-55.
Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020; 182: 1120-35.
Li A, Musters AH, Hyseni A, et al. Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. Br J Dermatol 2024; 191: 1012-3.
Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 2022; 10: 2695-709.
